MWI Veterinary Supply Inc. (MWIV, Financial) filed Quarterly Report for the period ended 2010-03-31.
Mwi Veterinary Supply Inc. has a market cap of $494.9 million; its shares were traded at around $40.5 with a P/E ratio of 18.6 and P/S ratio of 0.5. Mwi Veterinary Supply Inc. had an annual average earning growth of 20.5% over the past 5 years.MWIV is in the portfolios of Jim Simons of Renaissance Technologies LLC, Chuck Royce of Royce& Associates.
Our top ten vendors supplied products that accounted for approximately 70% of our revenues for each of the six months ended March 31, 2010 and 2009, respectively, and 74% of our revenues for the fiscal year ended September 30, 2009. Pfizer supplied products that accounted for approximately 26% of our revenues during each of the six months ended March 31, 2010 and 2009, respectively, and 24% of our revenues for our fiscal year ended September 30, 2009. Of the Pfizer supplied products, production animal products under a livestock agreement accounted for approximately 12% and 16% of our revenues during the six months ended March 31, 2010 and 2009, respectively, and approximately 14% of our revenues for our fiscal year ended September 30, 2009. Fort Dodge supplied products that accounted for 11% of our revenues during the six months ended March 31, 2009, and 11% of our revenues for our fiscal year ended September 30, 2009. Intervet-Schering, a subsidiary of Schering Plough, supplied products that accounted for approximately 11% and 10% of our revenues during the six months ended March 31, 2010 and 2009, respectively, and 11% of our revenues for our fiscal year ended September 30, 2009. Boehringer Ingelheim supplied products that accounted for approximately 9% and 4% of our revenues during the six months ended March 31, 2010 and 2009, respectively, and 4% of our revenues for our fiscal year ended September 30, 2009. Merial, a subsidiary of Sanofi-Aventis, supplies the majority of their products to us under an agency relationship. Commission revenue generated from Merial products accounted for approximately 52% of total commission revenues for each of the six months ended March 31, 2010 and 2009, and 56% of total commission revenues for our fiscal year ended September 30, 2009.
Read the The complete Report
Mwi Veterinary Supply Inc. has a market cap of $494.9 million; its shares were traded at around $40.5 with a P/E ratio of 18.6 and P/S ratio of 0.5. Mwi Veterinary Supply Inc. had an annual average earning growth of 20.5% over the past 5 years.MWIV is in the portfolios of Jim Simons of Renaissance Technologies LLC, Chuck Royce of Royce& Associates.
Highlight of Business Operations:
On October 15, 2009, Pfizer completed its acquisition of Wyeth. Prior to this acquisition, Pfizer and Fort Dodge, a division of Wyeth, were our two largest vendors as measured by our revenues. In connection with this acquisition, Pfizer divested certain animal health products to Boehringer Ingelheim. Fort Dodge supplied products that accounted for approximately 11% of our revenues for fiscal year 2009. Of this amount, based on information received from the Federal Trade Commission, Pfizer and Boehringer Ingelheim, we estimate that approximately 43% of such revenues were attributable to products now owned by Pfizer and approximately 57% of such revenues were attributable to products now owned by Boehringer Ingelheim. We have either received or reviewed contracts for calendar year 2010 from these vendors. Based on these contracts, we do not believe that the impact of the changes described will have a material impact on our results for fiscal year 2010.Our top ten vendors supplied products that accounted for approximately 70% of our revenues for each of the six months ended March 31, 2010 and 2009, respectively, and 74% of our revenues for the fiscal year ended September 30, 2009. Pfizer supplied products that accounted for approximately 26% of our revenues during each of the six months ended March 31, 2010 and 2009, respectively, and 24% of our revenues for our fiscal year ended September 30, 2009. Of the Pfizer supplied products, production animal products under a livestock agreement accounted for approximately 12% and 16% of our revenues during the six months ended March 31, 2010 and 2009, respectively, and approximately 14% of our revenues for our fiscal year ended September 30, 2009. Fort Dodge supplied products that accounted for 11% of our revenues during the six months ended March 31, 2009, and 11% of our revenues for our fiscal year ended September 30, 2009. Intervet-Schering, a subsidiary of Schering Plough, supplied products that accounted for approximately 11% and 10% of our revenues during the six months ended March 31, 2010 and 2009, respectively, and 11% of our revenues for our fiscal year ended September 30, 2009. Boehringer Ingelheim supplied products that accounted for approximately 9% and 4% of our revenues during the six months ended March 31, 2010 and 2009, respectively, and 4% of our revenues for our fiscal year ended September 30, 2009. Merial, a subsidiary of Sanofi-Aventis, supplies the majority of their products to us under an agency relationship. Commission revenue generated from Merial products accounted for approximately 52% of total commission revenues for each of the six months ended March 31, 2010 and 2009, and 56% of total commission revenues for our fiscal year ended September 30, 2009.
Read the The complete Report
